Synthetic hybrid peptide combining an AGA-modified humanin fragment with ADNF-9; studied preclinically for neuroprotection.
AGA-(C8R)HNG17 fused with ADNF-9. Much more potent than either parent peptide in neuronal-survival assays.
Evidence summary in progress. See the citations section below for the underlying research papers.
No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.
No documented drug interactions on file.
Not FDA approved. Research peptide.
Not available via 503A/503B compounding pharmacies.
Regulatory data last verified 4/19/2026
No indexed ClinicalTrials.gov studies for Colivelin. This usually means the compound isn't being studied under an IND — check the citations section for peer-reviewed research instead.
Showing 20 of 29 papers. View all on PubMed →